Loading...
XNAS
EVGN
Market cap7mUSD
May 02, Last price  
1.18USD
1D
2.61%
1Q
-24.84%
Jan 2017
-76.86%
IPO
-89.59%
Name

Evogene Ltd

Chart & Performance

D1W1MN
XNAS:EVGN chart
No data to show
P/E
—
P/S
0.93
EPS
—
Div Yield, %
—
Shrs. gr., 5y
-25.76%
Rev. gr., 5y
62.42%
Revenues
9m
+50.90%
14,901,00017,072,00017,581,00014,511,00011,129,0006,540,0003,381,0001,747,000753,0001,040,000930,0001,675,0005,640,0008,511,000
Net income
-16m
L-30.96%
645,000-2,522,000-8,878,000-14,530,000-17,213,000-19,592,000-20,838,000-20,758,000-18,112,000-23,374,000-27,793,000-26,638,000-23,879,000-16,485,000
CFO
-20m
L-8.70%
2,133,000-1,888,000-5,270,000-8,895,000-12,407,000-11,693,000-15,929,000-15,161,000-17,364,000-19,514,000-24,839,000-23,678,000-21,577,000-19,700,000
Earnings
May 21, 2025

Profile

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in multiple life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The CPB platform, incorporating a deep understanding of biology leveraged through big data and artificial intelligence, designed to computationally discover and uniquely guide the development of life-science products based on microbes, small molecules, and genetic elements. The company operates through three segments: Agriculture, Human Health, and Industrial Applications. The Agriculture segment develops seed traits, ag-chemical products, and ag-biological products to enhance plant performance. Its products focus on various crops, such as corn, soybean, wheat, rice, and cotton. The Industrial Applications segment develops enhanced castor bean seeds to serve as a feedstock source for other industrial uses. The Human Health segment discovers and develops human microbiome-based therapeutics for the treatment of immuno-oncology, GI related disorders, and antimicrobial resistance organisms. The company also provides medical cannabis products. It operates in the United States, Israel, Brazil, and internationally. The company has strategic collaborations and licensing agreements with agricultural companies, such as BASF SE, Corteva, and Bayer; and through its subsidiary, Canonic Ltd., has a collaboration agreement with Cannbit Ltd. for the development of novel medical cannabis products. Evogene Ltd. was founded in 1999 and is headquartered in Rehovot, Israel.
URL
https://evogene.com/
IPO date
Jun 11, 2007
Employees
137
Domiciled in
IL
Incorporated in
IL

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
8,511
50.90%
5,640
236.72%
1,675
80.11%
Cost of revenue
30,197
32,031
32,116
Unusual Expense (Income)
NOPBT
(21,686)
(26,391)
(30,441)
NOPBT Margin
Operating Taxes
9
(33)
90
Tax Rate
NOPAT
(21,695)
(26,358)
(30,531)
Net income
(16,485)
-30.96%
(23,879)
-10.36%
(26,638)
-4.16%
Dividends
Dividend yield
Proceeds from repurchase of equity
123
8,449
21
BB yield
-1.13%
-220.16%
-0.73%
Debt
Debt current
10,960
853
884
Long-term debt
4,417
11,791
12,862
Deferred revenue
4,327
4,426
4,665
Other long-term liabilities
90
393
18,432
Net debt
(16)
(18,419)
(21,609)
Cash flow
Cash from operating activities
(19,700)
(21,577)
(23,678)
CAPEX
(626)
(785)
(1,171)
Cash from investing activities
9,622
(4,538)
13,274
Cash from financing activities
4,656
18,152
9,343
FCF
(22,511)
(25,726)
(30,416)
Balance
Cash
15,311
31,063
35,355
Long term investments
82
Excess cash
14,967
30,781
35,271
Stockholders' equity
(257,419)
(240,668)
34,790
Invested Capital
289,548
285,678
35,027
ROIC
ROCE
EV
Common stock shares outstanding
5,807
4,569
4,121
Price
1.87
122.62%
0.84
20.00%
0.70
-57.32%
Market cap
10,859
182.97%
3,838
33.03%
2,885
-56.50%
EV
27,132
2,051
(11,864)
EBITDA
(19,182)
(23,779)
(27,861)
EV/EBITDA
0.43
Interest
63
171
3,329
Interest/NOPBT